Form 4: Sangamo Therapeutics CFO Sells Shares to Cover Tax Obligations After RSU Vesting

Sangamo Therapeutics' Chief Financial Officer, Prathyusha Duraibabu, sold shares to cover tax obligations following the vesting of restricted stock units.

Summary

• Prathyusha Duraibabu, the Senior Vice President and Chief Financial Officer of Sangamo Therapeutics, sold shares of common stock to cover tax obligations.
• These sales occurred on November 24, 2024, and November 25, 2024, following the vesting of restricted stock units (RSUs).
• On November 24, 2024, 1,787 shares were sold at $1.88 per share, and on November 25, 2024, 1,371 shares were sold at $1.94 per share.
• These transactions were not discretionary trades but were required for tax withholding purposes.
• After these transactions, Ms. Duraibabu beneficially owns 824,212 shares of Sangamo Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

This is a routine filing related to stock transactions by a company executive, which is common in publicly traded companies. It is not indicative of any specific trend in the biotechnology industry.

Comparison to Industry Standards

• The sale of shares by executives to cover tax obligations upon vesting of restricted stock units is a standard practice across publicly traded companies, including those in the biotechnology sector.
• Similar transactions are regularly reported by executives at companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, which are also in the gene editing space.
• The number of shares sold and the prices are typical for such transactions and are not unusual compared to similar filings from other companies.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and do not represent a discretionary sale by the CFO.
• The transactions do not impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Sangamo Therapeutics, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Tax Withholding, Prathyusha Duraibabu, SGMO